Filing Flows › Materials › Biolargo (BLGO)
Biolargo (BLGO) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · Biolargo (BLGO) Q2 2026 earnings results →
Q2 2026 Revenue down 55% year over year to $1.2M · 321¢ of every $1 of revenue lost · operating margin -298.7%
Biolargo made $1.2M in Q2 2026 (-55% Y/Y): Service $827K, Product $421K. Operating margin -298.7%, net loss $4.0M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.2M in Q2 2026, down 55% year over year and up 12% from the previous quarter. Service was the largest line at 66% of revenue. Product lost $1.6M year over year (down 79%), 104% of the total change.
Gross margin was 54.1%, up 2.9 points from Q2 2025. Operating costs exceeded revenue by $3.7M, an operating margin of -298.7%. Operating expenses grew 37% against a revenue fall of 55%. The fastest-growing cost line was Research & development (+103%). The quarter ended with a net loss of $4.0M, wider than the previous quarter's $3.4M loss. Minority interests bore $1.2M of it: to shareholders the quarter was a loss of $2.8M.
Operating cash flow was −$3.1M. Non-cash charges added back $31K of depreciation and $722K of share-based compensation. Working capital and other items added $191K.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $1.2M | -55% | -298.7% | −$4.0M | −$3.1M |
| Q1 2026 | 10-Q | May 15, 2026 | $1.1M | -66% | -287.4% | −$3.4M | −$2.9M |
| Q4 2025 | 10-K | Mar 4, 2026 | $617K | -83% | -650.1% | −$4.1M | −$1.6M |
| Q3 2025 | 10-Q | Nov 14, 2025 | $1.1M | -75% | -651.0% | −$7.2M | −$2.8M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $2.8M | -45% | -64.9% | −$1.9M | −$2.1M |
| Q1 2025 | 10-Q | May 15, 2025 | $3.3M | -31% | -57.0% | −$1.9M | −$1.8M |
| Q4 2024 | 10-K | Mar 31, 2025 | $3.7M | -16% | -44.2% | −$1.7M | −$1.9M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Biolargo
This annual report on Form 10-K for the year ended December 31, 2025 (the “Annual Report”) contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical fact, included in this Annual Report regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects and plans and objectives of management are forward-looking statements. These forward-looking statements include, but are not limited to, predictions regarding: You can identify these and other forward-looking statements by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions, or the negative of such terms, although not all forward-looking statements contain these identifying words.
In its own words, from its 10-K, filed Mar 4, 2026.
Biolargo against its Chemicals & Allied Products peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -55% against the peers' median +8%. Operating margin: -298.7% against the peers' median 8.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| BLGO Biolargo | Q2 2026 | $1.2M | -55% | -298.7% |
| OLN Olin | Q3 2026 | $1.7B | +2% | 3.4% |
| HUN Huntsman | Q3 2026 | $1.7B | +18% | 2.3% |
| Huntsman International LLC | Q2 2026 | $1.7B | +14% | 2.2% |
| CC Chemours | Q3 2026 | $1.5B | +3% | 14.4% |
| SOLS Solstice Advanced Materials | Q3 2026 | $1.0B | +8% | 10.7% |
| IOSP Innospec | Q3 2026 | $474M | +7% | 8.8% |
| PRM Perimeter Group | Q3 2026 | $390M | +24% | 106.8% |
| ECVT Ecovyst | Q3 2026 | $309M | +51% | 9.5% |
Source: Biolargo 10-Q on SEC EDGAR · CIK 880242 · Chemicals & Allied Products
More on BLGO
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results